NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India and South Asia, as the UK firm doubles down on high-growth markets. The move follows the company’s recent investment in China, highlighting the increasing role of emerging markets, which account for about 35% of its business but contribute more than half of its growth.

Haleon announces ₹2,000 crore investment to establish its first manufacturing facility in India, enhancing local oral care production and exports.

Haleon, the maker of Sensodyne, will invest £175 million to build its first oral health manufacturing plant in India, signaling strong confidence in the country's market potential.

NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India, underscoring the…